DC MPJE - independent pharmacy jurisprudence foundations key terms

The pharmacist's federal responsibility, shared with the prescriber, to assess whether a controlled prescription serves a legitimate medical purpose.

Federal registration authorizing specified controlled-substance activities, subject to its scope and other applicable legal authority.

A provider identifier used in standard health transactions, which does not itself grant controlled-substance prescribing authority.

A subsequent dispensing pursuant to remaining prescription authorization, distinct from the original fill or a partial quantity.

Dispensing less than the full prescribed quantity under a legally applicable pathway without increasing the total authorization.

A limited federal Schedule II exception with emergency-specific quantity, verification, documentation, and follow-up requirements.

The required periodic controlled-stock inventory conducted at least every two years following the applicable initial inventory.

The controlled-stock record at the beginning of regulated activity, including a record when no stock is on hand.

A legal product category that includes false or misleading labeling, rather than simply describing poor manufacturing conditions.

A legal product category covering specified quality or manufacturing defects, which may coexist with other regulatory violations.

An abbreviated drug application establishing applicable generic approval requirements rather than independently authorizing every local substitution.

An FDA-required product-specific risk-management strategy intended to ensure a medication's benefits outweigh its known serious risks.

A defined professional agreement specifying authorized drug-therapy activities, related conditions, and monitoring rather than unlimited independent prescribing.

Supplying a qualifying generically equivalent product under the applicable prescriber, purchaser, product, and local statutory conditions.

Replacing a prescribed therapy through the applicable authorization and consent process, distinct from ordinary generic-product substitution.

The District statutory notice identifying the biological product actually dispensed, including product name and manufacturer when required.

Enrollment required of specified practitioners and dispensers, separate from the duties to report dispensing and query patient history.

An authorized examination of prescription-monitoring information, with statutory triggers and exceptions distinct from reporting requirements.

Individually identifiable protected health information subject to applicable HIPAA privacy requirements, rather than all health-related facts.

A patient right to specified disclosure information over the applicable period, subject to exceptions including many treatment disclosures.